Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osimertinib + vemurafenib
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of osimertinib (a third-generation EGFR-tyrosine kinase inhibitor) and vemurafenib (a BRAF inhibitor) used to treat non-small cell lung cancer (NSCLC) patients with acquired BRAF V600E mutations following progression on EGFR-TKI therapy. This combination targets both EGFR mutations and BRAF V600E mutations simultaneously, making it effective for patients with heterogeneous tumors showing different molecular profiles across primary and metastatic lesions.
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)BRAF (B-Raf proto-oncogene, serine/threonine kinase)
Beyond the preview
Go deeper on osimertinib + vemurafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osimertinib + vemurafenib.